ARTICLE | Clinical News
Edarbyclor azilsartan medoxomil/chlorthalidone regulatory update
January 2, 2012 8:00 AM UTC
FDA approved an NDA from Takeda for Edarbyclor azilsartan/chlorthalidone to treat hypertension. The product is a fixed-dose combination of azilsartan, an angiotensin II type 1 (AT1) receptor blocker,...